{"schema_version":"secwatch.filing_event.v1","accession":"0001826667-25-000024","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.112632+00:00","generated_at":"2026-05-24T04:13:49.656491+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TriSalus reports FY 2024 revenue $29.4M (+59% YoY); delays 10-K due to accounting errors","bullets":["Q4 revenue $8.3M, FY revenue $29.4M (59% growth YoY); gross margin 86%.","Filing a Form 12b-25 for late 10-K due to errors in stock-based compensation and R&D expense timing.","Reaffirms 2025 guidance: >50% revenue growth, >20% OpEx reduction, positive EBITDA, positive cash flow H2 2025.","Cash $8.5M at Dec 31, plus $15M available under $50M OrbiMed credit facility.","Launched TriNav LV and TriGuide catheters; DELIVER program expanding addressable market to >$1B."],"urls":{"canonical":"https://secwatch.observer/filing/0001826667-25-000024","json":"https://secwatch.observer/filing/0001826667-25-000024.json","markdown":"https://secwatch.observer/filing/0001826667-25-000024.md","text":"https://secwatch.observer/filing/0001826667-25-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000024/0001826667-25-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000024/tlsi-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:13:49.656491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}